Analyst Price Targets — OVID
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 9, 2026 10:08 am | — | H.C. Wainwright | $4.00 | $2.88 | TheFly | Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright |
| December 11, 2025 10:14 am | Boobalan Pachaiyappan | Roth Capital | $3.00 | $1.63 | TheFly | Ovid Therapeutics initiated with a Buy at Roth Capital |
| November 24, 2025 11:17 am | — | H.C. Wainwright | $2.00 | $1.40 | TheFly | Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright |
| July 2, 2024 6:42 am | Raghuram Selvaraju | H.C. Wainwright | $3.00 | $0.86 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Ovid Therapeutics Inc (OVID) |
| May 20, 2024 5:32 am | Thomas Shrader | BTIG | $11.00 | $3.14 | StreetInsider | BTIG Reiterates Buy Rating on Ovid Therapeutics Inc (OVID) |
| May 14, 2024 3:13 pm | Francois Brisebois | Oppenheimer | $8.00 | $3.23 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Ovid Therapeutics Inc (OVID) |
Latest News for OVID
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the Company will host a KCC2 Deep Dive R&D event highlighting its first-in-class KCC2 portfolio on Tuesday, April 14, 2026, at 9:30 am ET in New York, NY, which will also be webcast simultaneously. During…
Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have received an average rating of "Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to
Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures after soticlestat's failure. Recent Phase 1 data show OV329 lacks the eye toxicity seen with vigabatrin, supporting its differentiated safety profile. Management secured $60M PIPE financing, extending the cash runway into 2029, but a $385.7M modeled funding gap implies 11% annual dilution over six years.
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OVID.
U.S. House Trading
No House trades found for OVID.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.